- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer Center
NCI CANCERLIT® Search: Therapy of Non-Hodgkin's Lymphoma - July 2002
National Cancer Institute®
Last Modified: July 1, 2002
- Large-cell lymphoma. An unusual late relapse.
- Denileukin diftitox for the treatment of panniculitic lymphoma.
- Healing from the inside out: one person's path with cutaneous T-cell lymphoma--mycosis fungoides.
- T-small cell disorders.
- Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma in children.
- Trimetrexate in relapsed T-cell lymphoma with skin involvement.
- Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's
- Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation
- Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II
- Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia.
- Risk-adapted therapy for relapsed and refractory lymphoma using ICE chemotherapy.
- Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma.
- Gigantic cutaneous lymphoma following Di Bella's therapy.
- Combined systemic and intrathecal chemotherapy plus radiotherapy in testicular lymphoma: a report of two cases.
- Treatment of cutaneous T-cell lymphoma with alitretinoin gel.
- Effectiveness of rituximab for chemotherapy-resistant multiple tumoral B-LPD in a haemopoietic stem cell recipient.
- [A case of malignant lymphoma of the stomach in which preoperative chemotherapy provided a complete response]
- [Effectiveness of prolonged oral administration of low-dose etoposide in a case of malignant lymphoma in the mesenterium]
- Treatment side effects. Case 2. Toxic, epidermal, necrolysis-like reaction associated with docetaxel chemotherapy.
- Primary central nervous system lymphomas.
- Immunotherapy of Non-Hodgkin's lymphomas.
- MALT Lymphomas.
- Involved-field irradiation in combination with total-body irradiation (TBI) does not increase short-term toxicity compared to TBI alone in
- Targeted treatment for non-Hodgkin's lymphoma.
- Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation.
- Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tiuxetan.
- Progress and promise in the treatment of indolent lymphomas.
- Challenges in treating hematologic malignancies.
- Cutaneous T-cell lymphoma/leukemia.
- MALToma versus marginal zone lymphoma versus diffuse large B cell lymphoma.
- Experience of two orbital MALT lymphomas treated with radiotherapy, and review of the literature.
- Phase II trial of sequential therapy with fludarabine followed by cyclophosphamide, mitoxantrone, vincristine, and prednisone for
- Successful treatment of non-Hodgkin's lymphoma complicated with autoimmune neutropenia.
- Impact of highly active antiretroviral therapy in the treatment of HIV-infected patients with systemic non-Hodgkin's lymphoma.
- Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma.
- [Systemic HIV-non-Hodgkin lymphoma in the era of HAART. Natural history]
- Anti-viral therapy for lymphoma.
- Anti-cancer agents. Hydroxyurea as anti-viral therapy for brain lymphoma.
- Anti-cancer agents. Curry for cancer?
- Therapy options in cutaneous T-cell lymphoma.
- [Primary lymphoma of the gastrointestinal tract]
- Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk
- Successful autologous peripheral blood stem cell transplantation in transformed follicular lymphoma previously treated with
- Evidence for T-large granular lymphocyte-mediated neutropenia in Rituximab-treated lymphoma patients: report of two cases.
- Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients.
- Radioimmunotherapy versus traditional, nontargeted forms of systemic cancer treatment.
Table of Contents
1
UI - 11553063
AU - Bowles KM; Tooze R; Marcus RE
TI -
Large-cell lymphoma. An unusual late relapse.
SO - Clin Lab Haematol 2001 Jun;23(3):197-9
AD - Department of Haematology, Addenbrookes Hospital, Cambridge, UK.
We report a case of a 40-year-old man with a stage 4, anaplastic,
large-cell lymphoma. He had been diagnosed 13 years before as having a
liposarcoma, at which point he was treated with combination
chemotherapy, which included anthracycline. On review of the
histopathology from 13 years before, the original diagnosis of
liposarcoma was revised to that of an anaplastic large-cell lymphoma. A
diagnosis of relapsed anaplastic large-cell lymphoma was made. A MUGA
scan showed a reduced ejection fraction of 46%. Our patient responded
initially to combination chemotherapy, which included anthracycline,
without further reduction in his ejection fraction. This was followed by
high-dose chemotherapy and peripheral blood stem-cell transplantation.
Twenty months later he is well and remains in complete remission.
2
UI - 12056952
AU - McGinnis KS; Shapiro M; Junkins-Hopkins JM; Smith M; Lessin SR; Vittorio
TI -
CC; Rook AH
Denileukin diftitox for the treatment of panniculitic lymphoma.
SO - Arch Dermatol 2002 Jun;138(6):740-2
AD - arook@mail.med.upenn.edu
3
UI - 12056954
AU - Yudle L
TI -
Healing from the inside out: one person's path with cutaneous T-cell
lymphoma--mycosis fungoides.
SO - Arch Dermatol 2002 Jun;138(6):748-50
AD - leahyudle@yahoo.com
4
UI - 12057122
AU - Westin EH; Longo DL
TI -
T-small cell disorders.
SO - Curr Treat Options Oncol 2001 Jun;2(3):225-35
AD - National Institute on Aging/NIH, 5600 Nathan Shock Drive, Baltimore, MD
21224-6825, USA.
A minority (less than 2%) of all lymphoproliferative disorders are
derived from small T cells. These include T-cell prolymphocytic
leukemia, T-cell granular lymphocytic leukemia, and mycosis
fungoides/Sezary syndrome. With the possible exception of early-stage,
skin-localized mycosis fungoides, all are considered incurable, although
palliation can be achieved with radiation therapy, chemotherapy,
biologic therapy, and combinations of these modalities. Of these
disorders, mycosis fungoides is the most common; it follows an indolent,
though gradually progressive, course that spans years. The T-cell
prolymphocytic leukemias, in contrast, are generally refractory to
treatment, with a median survival of typically less than 1 year.
Although effective therapy remains elusive in most cases, the
development of nucleosides as a class of chemotherapeutic agents and
biologics, including interferon, monoclonal antibodies, and vitamin A
derivatives, offers new hope for at least more effective palliation of
these progressive lymphoproliferative disorders. However, rapid
improvement in the treatment of these disorders remains hampered by the
rarity of these individual entities. More rapid progress in treatment
depends on national and international cooperation to accrue patients for
definitive trials of sufficient size to evaluate new treatment options
quickly.
5
UI - 12065554
AU - Spreafico F; Massimino M; Luksch R; Casanova M; Cefalo GS; Collini P;
TI -
Ferrari A; Polastri D; Terenziani M; Gasparini M; Fossati-Bellani F
Intensive, very short-term chemotherapy for advanced Burkitt's lymphoma
in children.
SO - J Clin Oncol 2002 Jun 15;20(12):2783-8
AD - Department of Pediatric Oncology, Istituto Nazionale Tumori, Milan,
Italy. f.spreafico@istitutotumori.mi.it
PURPOSE: To improve the 63% event-free survival (EFS) achieved before
1986 in Murphy's stage III to IV Burkitt's lymphoma (BL), both
chemotherapy and supportive care were intensified. PATIENTS AND METHODS:
2.1 to 17 years), with advanced BL were enrolled onto two sequential
institutional studies. From 1987 to 1992, 30 patients were stratified
according to the absence (regimen IA, n = 19) or presence (regimen IB, n
= 11) of bone marrow (BM) or CNS involvement. After 5-week cytoreductive
chemotherapy consisting of vincristine, cyclophosphamide, doxorubicin,
high-dose (HD) methotrexate (MTX), and intrathecal MTX or cytarabine, HD
cytarabine and cisplatin were provided as a 4-day continuous infusion.
Regimen IB was intensified by adding etoposide and HD ifosfamide and
escalating MTX doses. Since 1992, regardless of BM or CNS status, 30
patients have been placed on regimen II, which is identical to IB but
without ifosfamide. The scheduled duration of regimen II was 45 days.
RESULTS: EFS and disease-free survival at 5 years are 81% +/- 5% and 87%
+/- 5%, respectively, for 59 assessable patients (73% +/- 8% and 85% +/-
7% for regimen IA + IB, 89% +/- 6%, EFS and disease-free survival, for
regimen II; median follow-up, 6.7 years; range, 0.6 to 13.5 years). Six
patients, two of whom were receiving regimen II, died as a result of
initial treatment failure or relapse, and five patients, none receiving
regimen II, died as a result of treatment-related complications.
CONCLUSION: This 45-day intensive chemotherapy program is the shortest
schedule for disseminated BL and overcomes previously recognized risk
factors such as BM and CNS infiltration.
6
UI - 12065565
AU - Sarris AH; Phan A; Duvic M; Romaguera J; McLaughlin P; Mesina O; King K;
TI -
Medeiros LJ; Rassidakis GZ; Samuels B; Cabanillas F
Trimetrexate in relapsed T-cell lymphoma with skin involvement.
SO - J Clin Oncol 2002 Jun 15;20(12):2876-80
AD - Department of Lymphoma and Myeloma, University of Texas M.D. Anderson
Cancer Center, Houston, TX, USA. a.sarris@hygeia.gr
PURPOSE: Methotrexate (MTX) is active against lymphomas, but transport
or polyglutamylation mutations confer MTX resistance. Because
trimetrexate (TMTX) enters cells by passive diffusion and is not
polyglutamylated, its activity in relapsed T-cell lymphoma was
investigated. PATIENTS AND METHODS: Eligible patients had histologically
confirmed relapsed T-cell lymphoma involving the skin, had received more
than one previous regimen, were older than 16 years, had normal organ
function, and had no CNS disease or serious infections, including human
immunodeficiency virus. TMTX (200 mg/m(2)) was given intravenously every
14 days without topical or systemic corticosteroids. Patients who
responded received up to 12 doses. RESULTS: Twenty patients were
assessable for response. Median age was 59 years (range, 45 to 87
years); 13 patients were men. Three patients had anaplastic large-cell
lymphoma, 15 had mycosis fungoides or Sezary syndrome (14 with
large-cell transformation), and two had peripheral T-cell lymphoma.
Serum lactate dehydrogenase was high in 35%, and beta-2 microglobulin
was more than 3.0 mg/L in 35% of patients. The median number of previous
regimens was three (range, two to 15) and included MTX in five patients.
Disease was refractory to the regimen immediately preceding TMTX in 85%
of patients. Responses were complete in one and partial in eight
patients (overall response rate, 45%). Two of five patients previously
treated with MTX responded. Grade 3 or 4 mucositis was observed after
4%, infection after 3%, neutropenic fever after 6%, neutrophils less
than 100/microL after 4%, and platelets less than 10,000/microL after 3%
of TMTX doses. CONCLUSION: TMTX is active with acceptable toxicity in
this population and merits further investigation.
7
UI - 11896424
AU - Pavone V; Gaudio F; Guarini A; Perrone T; Zonno A; Curci P; Liso V
TI -
Mobilization of peripheral blood stem cells with high-dose
cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's
lymphoma.
SO - Bone Marrow Transplant 2002 Feb;29(4):285-90
AD - Haematology, University of Bari, Medical School, Policlinico Bari,
Italy.
Our study analyzes the mobilization of hematopoietic stem cells after
two chemotherapeutic regimens in non-Hodgkin's lymphoma (NHL) patients.
The study included 72 patients with NHL (42 follicular and 30 large
cells). The mean age was 37 years (range 17-60). Sixty-four patients
(88.9%) had stage III-IV disease. Forty-eight patients (66.7%) had bone
marrow involvement. Systemic B symptoms were present in 42 patients
(58.3%). Mobilization chemotherapy regimens were randomly assigned as
DHAP in 38 patients (52.7%) or cyclophosphamide (CPM) (5 g/m(2)) in 34
(47.2%) and the results of 132 procedures were analyzed. At the time of
PBSC mobilization, 46 patients (63.9%) were considered to be responsive
(complete remission, partial remission or sensitive relapse) and 26
(36.1%) not responsive (refractory relapse or refractory to therapy).
Pre-apheresis CD34+ blood cell count and number of previous chemotherapy
treatments were used to predict the total number of CD34+ cells in the
apheresis product. The mobilizing regimens (CPM or DHAP) were similar in
achieving the threshold CD34+ cell yield, for optimal engraftment. Since
DHAP was very effective as salvage treatment, we suggest using DHAP as a
mobilizing regimen in patients with active residual lymphoma at the time
of stem cell collection.
8
UI - 11896427
AU - Rapoport AP; Meisenberg B; Sarkodee-Adoo C; Fassas A; Frankel SR;
TI -
Mookerjee B; Takebe N; Fenton R; Heyman M; Badros A; Kennedy A; Jacobs
M; Hudes R; Ruehle K; Smith R; Kight L; Chambers S; MacFadden M;
Cottler-Fox M; Chen T; Phillips G; Tricot G
Autotransplantation for advanced lymphoma and Hodgkin's disease followed
by post-transplant rituxan/GM-CSF or radiotherapy and consolidation
chemotherapy.
SO - Bone Marrow Transplant 2002 Feb;29(4):303-12
AD - Greenebaum Cancer Center and Stem Cell Transplantation Program,
University of Maryland School of Medicine, Baltimore, MD, USA.
Disease relapse occurs in 50% or more of patients who are autografted
for relapsed or refractory lymphoma (NHL) or Hodgkin's disease (HD). The
administration of non-cross-resistant therapies during the
post-transplant phase could possibly control residual disease and delay
or prevent its progression. To test this approach, 55 patients with
relapsed/refractory or high-risk NHL or relapsed/refractory HD were
enrolled in the following protocol: stem cell mobilization:
cyclophosphamide (4.5 g/m(2)) + etoposide (2.0 g/m(2)) followed by
GM-CSF or G-CSF; high-dose therapy: gemcitabine (1.0 g/m(2)) on day -5,
BCNU (300 mg/m(2)) + gemcitabine (1.0 g/m(2)) on day -2, melphalan (140
mg/m(2)) on day -1, blood stem cell infusion on day 0; post-transplant
immunotherapy (B cell NHL): rituxan (375 mg/m(2)) weekly for 4 weeks +
GM-CSF (250 microg thrice weekly) (weeks 4-8); post-transplant
involved-field radiotherapy (HD): 30-40 Gy to pre-transplant areas of
disease (weeks 4-8); post-transplant consolidation chemotherapy (all
patients): dexamethasone (40 mg daily)/cyclophosphamide (300
mg/m(2)/day)/etoposide (30 mg/m(2)/day)/cisplatin (15 mg/m(2)/day) by
continuous intravenous infusion for 4 days + gemcitabine (1.0 g/m(2),
day 3) (months 3 + 9) alternating with dexamethasone/paclitaxel (135
mg/m(2))/cisplatin (75 mg/m(2)) (months 6 + 12). Of the 33 patients with
B cell lymphoma, 14 had primary refractory disease (42%), 12 had
relapsed disease (36%) and seven had high-risk disease in first CR
(21%). For the entire group, the 2-year Kaplan-Meier event-free survival
(EFS) and overall survival (OS) were 30% and 35%, respectively, while
six of 33 patients (18%) died before day 100 from transplant-related
complications. The rituxan/GM-CSF phase was well-tolerated by the 26
patients who were treated and led to radiographic responses in seven
patients; an eighth patient with a blastic variant of mantle-cell
lymphoma had clearance of marrow involvement after rituxan/GM-CSF. Of
the 22 patients with relapsed/refractory HD (21 patients) or high-risk T
cell lymphoblastic lymphoma (one patient), the 2-year Kaplan-Meier EFS
and OS were 70% and 85%, respectively, while two of 22 patients (9%)
died before day 100 from transplant-related complications. Eight
patients received involved field radiation and seven had radiographic
responses within the treatment fields. A total of 72 courses of
post-transplant consolidation chemotherapy were administered to 26 of
the 55 total patients. Transient grade 3-4 myelosuppression was common
and one patient died from neutropenic sepsis, but no patients required
an infusion of backup stem cells. After adjustment for known prognostic
factors, the EFS for the cohort of HD patients was significantly better
than the EFS for an historical cohort of HD patients autografted after
BEAC (BCNU/etoposide/cytarabine/cyclophosphamide) without consolidation
chemotherapy (P = 0.015). In conclusion, post-transplant consolidation
therapy is feasible and well-tolerated for patients autografted for
aggressive NHL and HD and may be associated with improved
progression-free survival particularly for patients with HD.
9
UI - 12036859
AU - Wiseman GA; Gordon LI; Multani PS; Witzig TE; Spies S; Bartlett NL;
TI -
Schilder RJ; Murray JL; Saleh M; Allen RS; Grillo-Lopez AJ; White CA
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or
refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II
multicenter trial.
SO - Blood 2002 Jun 15;99(12):4336-42
AD - Division of Nuclear Medicine, Mayo Clinic, Rochester, MN 55905, USA.
gwiseman@mayo.edu
Mildly thrombocytopenic patients with relapsed or refractory low-grade
non-Hodgkin lymphoma (NHL) have an increased risk of
chemotherapy-induced myelosuppression following treatment. The safety
and efficacy of radioimmunotherapy with a reduced dose of (90)Y
ibritumomab tiuxetan (0.3 mCi/kg [11 MBq/kg]; maximum 32 mCi [1.2 GBq])
was evaluated in 30 patients with mild thrombocytopenia (100-149 x 10(9)
platelets/L) who had advanced, relapsed or refractory, low-grade,
follicular, or transformed B-cell NHL. The ibritumomab tiuxetan regimen
included an infusion of rituximab (250 mg/m(2)) and injection of (111)In
ibritumomab tiuxetan (5 mCi [185 MBq]) for dosimetry evaluation,
followed 1 week later with rituximab (250 mg/m(2)) and (90)Y ibritumomab
tiuxetan (0.3 mCi/kg [11 MBq/kg]). Patients (median age, 61 years; 90%
stage III/IV at study entry; 83% follicular lymphoma; and 67% with bone
marrow involvement) had a median of 2 prior therapy regimens (range,
1-9). Estimated radiation-absorbed doses were well below the
study-defined maximum allowable for all 30 patients. With the use of the
International Workshop criteria for NHL response assessment, the overall
response rate was 83% (37% complete response, 6.7% complete response
unconfirmed, and 40% partial response). Kaplan-Meier estimated median
time to progression (TTP) was 9.4 months (range, 1.7-24.6). In
responders, Kaplan-Meier estimated median TTP was 12.6 months (range,
4.9-24.6), with 35% of data censored. Toxicity was primarily
hematologic, transient, and reversible. The incidence of grade 4
neutropenia, thrombocytopenia, and anemia was 33%, 13%, and 3%,
respectively. Reduced-dose ibritumomab tiuxetan is safe and well
tolerated and has significant clinical activity in this patient
population.
10
UI - 12036865
AU - Hoelzer D; Gokbuget N; Digel W; Faak T; Kneba M; Reutzel R;
TI -
Romejko-Jarosinska J; Zwolinski J; Walewski J
Outcome of adult patients with T-lymphoblastic lymphoma treated
according to protocols for acute lymphoblastic leukemia.
SO - Blood 2002 Jun 15;99(12):4379-85
AD - Medical Clinic III, Department of Hematology, University of Frankfurt,
Germany. hoelzer@em.uni-frankfurt.de
We treated 45 adult patients with T-lymphoblastic lymphoma (T-LBL) (age
range 15-61 years) with 2 protocols designed for adult acute
lymphoblastic leukemia (ALL). An encouraging cure rate of 90% was
recently reported for T-LBL in children treated with a similar approach.
In our study, an 8-drug standard induction was administered over 8 weeks
including prophylactic cranial (24 Gy) and mediastinal irradiation (24
Gy) followed by consolidation and reinduction therapy. At diagnosis, 91%
of the 45 patients showed a mediastinal tumor and 40% had
pleural/pericardial effusions; 73% of the patients had stage III/IV
disease. Overall, 42 patients (93%) achieved a complete remission (CR),
2 patients (4%) achieved a partial remission, and 1 patient (2%) died
during induction. In patients with stage I-III disease (n = 18) the CR
rate was 100% compared with 89% in stage IV (n = 27). There were 15
patients who relapsed (36%) within 12 months. The majority of relapses
(47%) occurred in the mediastinum (n = 7) despite mediastinal
irradiation with 24 Gy in 6 out of 7 patients. The estimates for overall
survival, continuous CR, and disease-free survival at 7 years are 51%,
65%, and 62%, respectively. Stage, age, lactate dehydrogenase, and all
other parameters had no influence on achievement of CR or outcome. This
study demonstrates in a large cohort of patients with adult T-LBL that a
high CR rate and a favorable outcome can be achieved with an ALL-type
regimen. Mediastinal recurrence was the major obstacle and further
improvement by intensification of chemotherapy, increased dose of
mediastinal irradiation (36 Gy), and extended indications for stem cell
transplantation seem to be required.
11
UI - 12042983
AU - Moskowitz C
TI -
Risk-adapted therapy for relapsed and refractory lymphoma using ICE
chemotherapy.
SO - Cancer Chemother Pharmacol 2002 May;49 Suppl 1():S9-12
AD - Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY,
USA. moskowic@mskcc.org
At Memorial Sloan Kettering Cancer Center, New York, we have treated
over 400 patients with ICE chemotherapy after failure of upfront
anthracycline-based therapy with a response rate of 72% in aggressive
non-Hodgkin's lymphoma (NHL) and 84% in Hodgkin's disease. Utilizing
this database, we have identified pretreatment prognostic markers
capable of predicting the quality of response (complete response vs
partial response vs failure) to second-line cytoreductive ICE
chemotherapy and consequently autologous stem cell transplantation. We
have shown that in aggressive NHL, patients achieving a complete
response have superior survival when compared to those achieving only a
partial response. By identifying a priori those patients destined to
have only a partial response to ICE, we will be able to target a group
of chemosensitive patients who are most likely to benefit from improved
treatment. Novel treatment strategies designed to increase their
complete response rate would be anticipated to improve their long-term
survival.
12
UI - 11940484
AU - Barrios Y; Cabrera R; Yanez R; Briz M; Plaza A; Fores R; Fernandez MN;
TI -
Diaz-Espada F
Anti-idiotypic vaccination in the treatment of low-grade B-cell
lymphoma.
SO - Haematologica 2002 Apr;87(4):400-7
AD - Departments of Immunology, Clinica Puerta de Hierro, Madrid, Spain.
BACKGROUND AND OBJECTIVES: Patients with B-cell lymphoma can be induced
to mount a specific immune response against the individual idiotypic
determinants expressed in their tumor cells. This form of active
immunotherapy is now under evaluation in the clinical setting. We
evaluated the feasibility and effectiveness of this kind of
immunotherapy in a group of patients with low-grade lymphoma, which
included two cases of bi/triclonal lymphoma. DESIGN AND METHODS: Nine
patients with a histopathologic diagnosis of follicular non-Hodgkin's
(NHL) low-grade B-cell lymphoma were initially selected for this
disease-free survival study. Idiotypic proteins were recovered by
somatic fusion of the tumor cells and their identity with the tumor
idiotype determined by molecular methods. The patients received the
vaccine consisting of their tumor Ig protein coupled to keyhole limpet
hemocyanine and were observed for toxicity, anti-idiotypic immune
response, clinical outcome and circulating t(14;18)+ tumor cells.
RESULTS: The median duration of follow-up was 40 (10-64) months from the
initiation of immunotherapy. Tumor regression was detected in two
patients. No tumor progression was observed in the other patients. Eight
patients generated specific anti-idiotypic antibodies and 3 out of five
were cleared of circulating t(14;18)+ cells. INTERPRETATION AND
CONCLUSIONS: Induction of tumor-specific anti-idiotypic immune responses
may be of benefit to patients affected by low-grade B-cell NHL. Our
results are in line with those previously reported and call attention to
the issue of tumor clonality in this kind of treatment.
13
UI - 11940500
AU - Bassan R; Reseghetti A; Cortelazzo S; Rossi A; Buelli M; Viero P; Barbui
TI -
T
Gigantic cutaneous lymphoma following Di Bella's therapy.
SO - Haematologica 2002 Apr;87(4):EIM13
AD - U.O. Ematologia, Ospedali Riuniti, largo Barozzi 1, 24100 Bergamo,
Italy. basbas@virgilio.it
14
UI - 11940507
AU - Magagnoli M; Balzarotti M; Castagna L; Bertuzzi A; Nozza A; Santoro A
TI -
Combined systemic and intrathecal chemotherapy plus radiotherapy in
testicular lymphoma: a report of two cases.
SO - Haematologica 2002 Apr;87(4):ELT22
AD - Departmenti of Medical Oncology and Hematology, Istituto Clinico
Humanitas- Via Manzoni 56, 20089 Rozzano, Italy.
massimo.magagnoli@humanitas.it
15
UI - 11982647
AU - Bassiri-Tehrani S; BA BA; Cohen DE
TI -
Treatment of cutaneous T-cell lymphoma with alitretinoin gel.
SO - Int J Dermatol 2002 Feb;41(2):104-6
AD - Department of Dermatology, New York University School of Medicine, New
York 10016, USA.
16
UI - 12028061
AU - Imashuku S; Naya M; Tamura S; An B; Teramura T; Kobayashi M; Nomura K;
TI -
Taniwaki M
Effectiveness of rituximab for chemotherapy-resistant multiple tumoral
B-LPD in a haemopoietic stem cell recipient.
SO - Br J Haematol 2002 Jun;117(3):771-3
17
UI - 12090049
AU - Okumoto T; Tomiyama K; Ino H; Kanaya Y; Maruyama S; Otani J; Yokoyama N;
TI -
Soda M
[A case of malignant lymphoma of the stomach in which preoperative
chemotherapy provided a complete response]
SO - Gan To Kagaku Ryoho 2002 Jun;29(6):943-7
AD - Dept. of Surgery, Himeji St. Mary's Hospital.
We have encountered a case of malignant lymphoma of the stomach in which
a complete remission was confirmed in a resected specimen after
chemotherapy. A 75-year-old woman complained of vomiting blood. A biopsy
from gastric endoscopy indicated malignant lymphoma of diffuse large
B-cell type. The patient was assumed to be inoperable due to enlargement
of the tumor and lymph node metastasis, and THP-COP chemotherapy was
carried out. After four courses of the THP-COP regimen, endoscopic
examination revealed a significant tumor reduction. Total gastrectomy
and splenectomy with lymph node dissection (D2) were performed after
chemotherapy. No tumor cells were detected in any sections of the
specimen or regional lymph nodes.
18
UI - 12090052
AU - Sato T; Yanagihara M; Sato K; Nozawa T; Furukawa Y; Imanishi H; Kouzuma
TI -
T
[Effectiveness of prolonged oral administration of low-dose etoposide in
a case of malignant lymphoma in the mesenterium]
SO - Gan To Kagaku Ryoho 2002 Jun;29(6):959-62
AD - Dept. of Surgery, Yokohama Seamens' Insurance Hospital.
Malignant lymphoma in the mesenterium is rare and carries a poor
prognosis, although curative resection cases have been reported. A
39-year-old woman with non-resectable mesenteric malignant lymphoma
obtained a better QOL and outcome from prolonged oral administration of
low-dose etoposide as a maintenance therapy after CHOP therapy.
19
UI - 12089234
AU - Dourakis SP; Sevastianos VA; Alexopoulou A; Deutsch M; Stavrianeas N
TI -
Treatment side effects. Case 2. Toxic, epidermal, necrolysis-like
reaction associated with docetaxel chemotherapy.
SO - J Clin Oncol 2002 Jul 1;20(13):3030-2
AD - Hippokration General Hospital and Sigrou Hospital, Athens, Greece.
20
UI - 12057111
AU - DeAngelis LM
TI -
Primary central nervous system lymphomas.
SO - Curr Treat Options Oncol 2001 Aug;2(4):309-18
AD - Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY
10021-6700, USA. deangell@mskcc.org
Primary central nervous system lymphoma (PCNSL) is widely regarded as
one of the primary brain tumors most amenable to treatment. Although
whole brain radiotherapy was the cornerstone of therapy for decades,
recent work clearly indicates that chemotherapy has become the primary
focus of treatment for this disease. The initial treatment of PCNSL for
all patients, including the elderly, should be chemotherapy using a
high-dose methotrexate-based regimen. Although cranial irradiation has
often been combined with methotrexate, the unacceptably high incidence
of late neurotoxicity, particularly in older patients, has caused many
to eliminate radiotherapy, especially in those older than age 60 years.
Emerging data support the validity of this approach, and the development
of more efficacious chemotherapeutic regimens has been the focus of
recent research.
21
UI - 11722986
AU - Press OW; Leonard JP; Coiffier B; Levy R; Timmerman J
TI -
Immunotherapy of Non-Hodgkin's lymphomas.
SO - Hematology (Am Soc Hematol Educ Program) 2001;():221-40
AD - Clinical Research Division, Fred Hutchinson Cancer Research Center,
Seattle, WA 98109, USA.
Recent years have witnessed the development of a variety of promising
immunotherapies for treating patients with non-Hodgkin's lymphomas.
Foremost among these advances is the exciting success of monoclonal
antibodies directed against lymphocyte surface antigens. Rituximab is a
chimeric (human-mouse) anti-CD20 antibody that induces responses in
approximately half of the patients with relapsed indolent lymphomas and
a third of patients with relapsed aggressive lymphomas when used as a
single agent. Response rates appear even higher (up to 70%) for newly
diagnosed patients treated with Rituximab monotherapy. Other promising
antibodies for treatment of B cell malignancies include epratuzumab
(anti-CD22), CAMPATH-1H (anti-CD52w), and Hu1D10 (anti-class II HLA).
Even more exciting than antibody monotherapy is the prospect of
combination antibody therapy (e.g. rituximab + epratuzumab) or
combination chemotherapy and antibody therapy. In this regard, a recent
phase III randomized trial from the GELA group in France demonstrated
statistically significantly superior complete and overall response rates
and superior event-free and overall survivals for elderly patients with
newly diagnosed diffuse aggressive B cell lymphomas treated with CHOP +
rituximab compared with CHOP alone. Confirmatory cooperative group
trials combining chemotherapy with antibody therapies are currently
underway. Another approach to augment the efficacy of antibodies is to
deploy them in radiolabeled form. Iodine-131, Yttrium-90, and Copper-67
labeled monoclonal antibodies targeting CD-20, CD-22, HLA class II, and
other cell surface antigens have been tested and demonstrate higher
overall response rates (50-80%) and complete response rates (20-40%)
than unlabeled antibodies. Pilot studies combining radiolabeled
antibodies with either standard dose chemotherapy or myeloablative
chemoradiotherapy with stem cell transplantation also appear very
promising. Lymphoma vaccines have also produced very encouraging results
in single institution studies at Stanford and the National Cancer
Institute, with responding patients demonstrating superior event-free
and overall survival than historical controls. Phase III randomized
trials of idiotype vaccines are currently underway and novel new vaccine
approaches are also being tested.
22
UI - 11722987
AU - Cavalli F; Isaacson PG; Gascoyne RD; Zucca E
TI -
MALT Lymphomas.
SO - Hematology (Am Soc Hematol Educ Program) 2001;():241-58
AD - Oncology Institute of Southern Switzerland, Department of Medical
Oncology.
This review addresses the biology and the treatment of lymphomas arising
from mucosa-associated lymphoid tissue (MALT). This entity, first
described in 1983, represents about 8% of all non-Hodgkin's lymphomas
and was recently re-classified as "extranodal marginal zone lymphomas of
MALT-type." The term marginal zone lymphoma (MZL) encompasses the three
closely related lymphoma subtypes of nodal, primary splenic and
extranodal lymphomas of MALT type: the latter represent the vast
majority of MZL. These lymphomas arise at different anatomic sites, are
composed of mature B-cells lacking expression of CD5 and CD10, often
present with overlapping morphologic features, but typically quite
distinct clinical behaviors. Only very recently cytogenetic/molecular
genetic observations have underlined the distinctiveness of these three
lymphoid neoplasms, which in both the R.E.A.L. and WHO-classifications
are included in the general term of MZL. MALT lymphomas arise in
numerous extranodal sites, but gastric MALT lymphoma is the most common
and best studied and is, therefore, the paradigm for the group as a
whole. Dr. Isaacson describes the principal histological features of
these lymphomas, including criteria to distinguish this entity from
other small B-cell lymphomas. Several lines of evidence suggest that
gastric lymphoma arises from MALT acquired as the result of aH.
pyloriinfection. However, at least 1/3 of cases do not respond to
eradication ofH. pylori. Very recent data suggest that both t(11;18)
(q21;q21) and bcl10 nuclear expression are associated with failure to
respond to this treatment. Dr. Gascoyne discusses the biologic function
of proteins deregulated through the different translocations, which play
a role in pathogenesis of MALT lymphomas, emphasizing particularly their
influence in disrupting the apoptotic pathway. Dr. Zucca reviews
findings suggesting that MALT lymphoma is an antigen driven neoplasm. He
also presents specific guidelines for treatment of gastric lymphomas
trying to shed some light on the amazingly inconsistent and confusing
data in the literature. Taking advantage on the more than 300
non-gastric MALT lymphomas collected by the International Extranodal
Lymphoma Study Group (ILESG), Dr. Cavalli compares gastric lymphomas
with those arising in many other sites. Overall, the data presented in
this session will underline the fact, that MALT lymphomas are
characterized by some unique biological properties.
23
UI - 12082683
AU - Ott M; Schmidberger H; Wormann B; Albrecht CF; Pradier O; Hess CF
TI -
Involved-field irradiation in combination with total-body irradiation
(TBI) does not increase short-term toxicity compared to TBI alone in
patients with advanced-stage low-grade non-Hodgkin lymphoma.
SO - Strahlenther Onkol 2002 May;178(5):245-51
AD - Department of Radiotherapy, University of Goettingen, Germany.
PURPOSE: High-dose therapy (HDT) is currently under investigation for
patients with advanced low-grade non-Hodgkin lymphoma (NHL). We report
on the toxicity of a modified HDT that combines total-body irradiation
(TBI) with involved-field irradiation (IF-RT) for patients with bulky
disease or residual lymphomas > 2 cm after induction chemotherapy.
PATIENTS AND METHODS: 41 patients received HDT which consisted of
high-dose cyclophosphamide and fractionated TBI (6 x 2 Gy) followed by
autologous stem cell transplantation. Eleven patients received IF-RT
prior to TBI, three patients had already received another radiotherapy
treatment prior to HDT. RESULTS: After a medium follow-up of 19 months
we observed an overall survival rate of 100%, and a relapse-free
survival rate of 78%. Severe toxicity was observed only in one patient
who developed a myelodysplastic syndrome, and another patient who showed
signs of pneumonitis. About two thirds of the patients claimed minor
toxicity of grade I-II according the LENT-SOMA scale, predominantly as a
decrease in concentration, reduced sexual functioning, and
musculo-skeletal pain. Correspondingly, laboratory tests showed grade
I-II changes of blood counts, liver enzymes, hormone levels, and lung
function. There was no excess toxicity in the patients who received
IF-RT additional to TBI. CONCLUSIONS: HDT including TBI and prior IF-RT
is feasible without excess morbidity. Careful follow-up is required to
detect myelodysplastic syndrome or endocrine changes of ovarian or
testicular function.
24
UI - 12132412
AU - Anonymous
TI -
Targeted treatment for non-Hodgkin's lymphoma.
SO - Health News 2002 May;8(5):7
25
UI - 12077596
AU - Masood N; Russell KJ; Olerud JE; Sabath DE; Sale GE; Doney KC; Flowers
TI -
ME; Fefer A; Thompson JA
Induction of complete remission of advanced stage mycosis fungoides by
allogeneic hematopoietic stem cell transplantation.
SO - J Am Acad Dermatol 2002 Jul;47(1):140-5
AD - Fred Hutchinson Cancer Research Center, University of Washington School
of Medicine, Seattle, WA 98109-1023, USA.
Advanced mycosis fungoides (MF) is incurable with conventional
treatments. High-dose chemoradiotherapy with autologous bone marrow
transplantation has induced remissions in a small number of patients
with MF, but this modality is limited by a high relapse rate. We report
induction of complete remission in a 37-year-old woman with rapidly
progressive stage IV MF with allogeneic stem cell transplantation (Allo
SCT). She remains in continuous complete remission 2 years after
transplant. Allo SCT for MF is theoretically attractive, because there
is no contamination of the graft by malignant cells, and because of the
possibility of graft-versus-tumor effect. Although the results in this
patient are encouraging, more patients and longer follow-up are needed
to define the usefulness of Allo SCT in the treatment of MF.
26
UI - 11998607
AU - Hendrix CS; de Leon C; Dillman RO
TI -
Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90
ibritumomab tiuxetan.
SO - Clin J Oncol Nurs 2002 May-Jun;6(3):144-8
AD - chendrix@hoaghospital.org
The increasing incidence of non-Hodgkin's lymphoma (NHL), coupled with
the lack of optimal treatment options, has prompted the development of
novel treatments. Of these, radioimmunotherapy is one of the most
promising. Two of the radiolabeled monoclonal antibody therapies being
studied in the treatment of NHL are yttrium 90 (90Y) ibritumomab
tiuxetan and iodine 131 (131I) tositumomab. The radionuclides 90Y and
131I emit beta radiation; 131I also emits gamma radiation, thus
requiring more elaborate precautionary measures to limit radiation
exposure. The monoclonal antibody portions of the drugs target the CD20
surface antigen that is present on the majority of B-cell lymphomas,
resulting in direct radiation to the targeted cells, as well as indirect
targeting of adjacent cells (known as the crossfire effect). Clinical
trials of 90Y ibritumomab tiuxetan in patients with NHL have produced
promising results. The safe and effective use of radioimmunotherapy
requires a multidisciplinary team approach in which nurses play a
central role.
27
UI - 12065794
AU - McLaughlin P
TI -
Progress and promise in the treatment of indolent lymphomas.
SO - Oncologist 2002;7(3):217-25
AD - University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030,
USA. pmclaugh@mail.mdanderson.org
In the era of conventional alkylating agent-based chemotherapy, advanced
stage indolent lymphoma has been considered incurable. The failure of
our traditional therapies to cure these patients, coupled with the
indolent course of the disease and the elderly population affected, has
fostered a nihilistic attitude about the treatment of these diseases.
Twenty years ago, in the absence of interesting alternatives to
alkylating agents, judicious use and reuse of alkylators was perhaps the
best we could do. There are now many reasons for optimism and excitement
in the treatment of these diseases, including the availability of
promising agents such as interferon-alpha, the nucleoside analogues, and
rituximab. Radioimmunotherapy will also likely play a role in future
therapy programs. Allogeneic stem cell transplantation is a high-risk
approach that is not an option for all patients, but it has the
potential to cure patients, even in the setting of relapse.
Mini-allogeneic transplantation may permit an approach to allogeneic
transplantation that is better tolerated than standard transplant
strategies. In addition to these therapy options, biological insights
have provided new options for monitoring patients. Molecular monitoring
(polymerase chain reaction for bcl-2) is a stringent measure of
short-term treatment efficacy, and one that correlates with durability
of remission, i.e., it is a surrogate marker by which to judge treatment
efficacy. There used to be a limited number of conventional treatment
approaches, which consistently failed. The pendulum has swung. There are
now many promising new options. It is time to plan and conduct trials
that are geared for success.
28
UI - 12082652
AU - Voliotis D; Diehl V
TI -
Challenges in treating hematologic malignancies.
SO - Semin Oncol 2002 Jun;29(3 Suppl 8):30-9
AD - Clinic I for Internal Medicine, University of Cologne, Cologne, Germany.
During the past 40 years substantial progress has been made in the
treatment of hematologic malignancies, particularly in some subgroups of
patients. Today, cure is attainable for patients with Hodgkin's disease
and a considerable proportion of patients with high-grade non-Hodgkin's
lymphoma. Prognosis is improving in patients with acute promyelocytic
leukemia and, to some extent, those with acute lymphoblastic and myeloid
leukemias. However, the majority of patients who suffer from a
hematologic malignancy live with incurable disease. In CLL, outside the
setting of a clinical trial, it is advisable to postpone treatment until
the manifestation of clinical symptoms. It is yet to be determined
whether treatment strategies based on new prognostic parameters such as
cytogenetics can change the course of disease. In indolent lymphomas,
cure is not attainable for the vast majority of patients; the median
survival of 9 to 10 years has remained unchanged for several decades.
Nevertheless, there has been a dramatic change in therapeutic paradigms
in the past few years. For the first time, with the use of new
cytostatic drugs and recombinant monoclonal antibodies, it is possible
to achieve molecular remissions. Whether this will translate into cure
or prolonged survival is still to be determined. In Hodgkin's disease,
which is curable when treated with radiotherapy, chemotherapy, or
combined therapy, depending on the stage of disease, the focus of future
studies must be on prevention of early relapse and on primary resistant
disease, both of which present a very poor prognosis. Finally,
regardless of underlying malignancy and prognosis, the preservation of
quality of life is of major consideration in the setting of hematologic
malignancies. Copyright 2002, Elsevier Science (USA). All rights
reserved.
29
UI - 12057060
AU - Siegel RS; Kuzel TM
TI -
Cutaneous T-cell lymphoma/leukemia.
SO - Curr Treat Options Oncol 2000 Apr;1(1):43-50
AD - Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Medical School, 676 N. St. Clair, Suite 850, Chicago, IL 60611, USA.
Effective treatment for cutaneous T-cell lymphomas (CTCL) requires an
accurate and specific diagnosis based on the clinical presentation
combined with evaluation of the histopathology, immunophenotyping, and
gene rearrangement studies. Careful clinical and pathologic evaluation
in centers familiar with the diverse forms of CTCL is most valuable for
determining treatment options. The goals of treatment in mycosis
fungoides (MF), which afflicts more than 50% of patients with CTCL, are
the relief of symptoms and improvement in cosmetics. Despite some
uncontrolled clinical trial results that have been reported to suggest
"cures" in this disease, the general perception remains that this
disease is not curable with standard therapies available today.
Treatment is divided into topical (skin-directed) and systemic therapy.
The most active systemic agent for the treatment of MF remains
interferon-alpha, although many new modalities have recently been
approved for the treatment of CTCL.
30
UI - 11966958
AU - Ely SA
TI -
MALToma versus marginal zone lymphoma versus diffuse large B cell
lymphoma.
SO - J Gastroenterol Hepatol 2002 Feb;17(2):226; discussion 226-7
31
UI - 11837584
AU - Komatsu T; Kikuchi Y; Nisijima H; Takanaka T; Terayama N; Matsui O
TI -
Experience of two orbital MALT lymphomas treated with radiotherapy, and
review of the literature.
SO - Radiat Med 2001 Nov-Dec;19(6):317-20
AD - Department of Radiology, Kanazawa University School of Medicine, Japan.
Orbital MALT lymphoma is a relatively rare malignant disease, for which
radiation therapy is effective. However, the optimal dose has not been
determined. We experienced two cases of orbital MALT lymphoma. One
patient was successfully treated, but the other developed a severe
complication. We conclude that for safe treatment of orbital MALT
lymphoma, a dose in excess of 40 Gy must not be delivered.
32
UI - 12111762
AU - Rohatgi N; LaRocca RV; Bard V; Sethuraman G; Foon KA
TI -
Phase II trial of sequential therapy with fludarabine followed by
cyclophosphamide, mitoxantrone, vincristine, and prednisone for
low-grade follicular lymphomas.
SO - Am J Hematol 2002 Jul;70(3):181-5
AD - The Barrett Cancer Center and the Division of Hematology/Oncology,
Department of Medicine, University of Cincinnati, Cincinnati, Ohio, USA.
Advanced follicular lymphomas, grades I and II, are indolent tumors but
are not considered curable with standard therapy. Fludarabine has the
highest single-agent response rates in this disease. However,
fludarabine-based combination chemotherapy regimens have been associated
with significant myelotoxicity. Data exist suggesting that the best way
to combine partially non-cross-resistant agents may be to use them
sequentially. Patients with bulky stage II, stage III, or stage IV
follicular lymphoma (grade I or II) were entered on this protocol.
Patients were treated with 3 cycles of fludarabine followed by 6-8
cycles of cyclophosphamide, mitoxantrone, vincristine, and prednisone
(CNOP). Response was assessed after the 3(rd) cycle of fludarabine and
after the 4(th), 6(th), and 8(th) cycles of CNOP. Twenty-seven patients
were entered on the protocol. Median follow-up was 50 months. Eighteen
patients (67%) attained a complete response (CR), and eight patients
(30%) attained a partial response (PR), for an overall response rate of
97%. Median relapse-free survival was 34 months, and median overall
survival was not reached for the entire cohort. While all patients who
achieved only PR progressed, more than half of those in CR remain free
of progression at 39-84 months of follow-up. The regimen was well
tolerated. The sequential combination of fludarabine and CNOP appears to
be active and well tolerated in patients with grade I and II follicular
lymphoma. Patients who achieve CR fare best, and many remain
disease-free long term. While these results are encouraging, the
addition of other active agents such as rituximab to this regimen may
further enhance efficacy and is under investigation. Copyright 2002
Wiley-Liss, Inc.
33
UI - 12111776
AU - Nakabe N; Kobayashi Y; Nakajima T; Hattori T; Kuroda J; Kimura S;
TI -
Yoshikawa T
Successful treatment of non-Hodgkin's lymphoma complicated with
autoimmune neutropenia.
SO - Am J Hematol 2002 Jul;70(3):264-5
34
UI - 12102166
AU - Baiocchi OC; Colleoni GW; Navajas EV; Duarte LC; Alves AC; Andrade AL;
TI -
Kerbauy J; Oliveira JS
Impact of highly active antiretroviral therapy in the treatment of
HIV-infected patients with systemic non-Hodgkin's lymphoma.
SO - Acta Oncol 2002;41(2):192-6
AD - Hematology and Transfusion Service, Universidade Federal de Sao Paulo,
Brazil.
Twenty cases of systemic non-Hodgkin's lymphoma (NHL) in HIV-infected
patients were reviewed over a 10-year-period, divided into Group A,
including 13 NHL cases treated before the highly active antiretroviral
therapy (HAART) era, and Group B, including 7 patients who received
HAART. A Kaplan-Meier survival curve was performed and log-rank was
applied to assess statistical differences between the groups. In group
A, the median CD4 count was 36 cells/mm3. No complete remission was
found. In group B, the median CD4 count was 137 cells/mm3. Four patients
(57.0%) are still alive and in complete remission. Group A had a median
survival of 5 months and group B 31 months (p = 0.0032). Our results are
in agreement with recent reports in that a higher CD4 count and better
immune status achieved with HAART is predictive of a better outcome. We
found that HAART in combination with chemotherapy improves overall
survival of NHL patients without increasing adverse effects.
35
UI - 12060818
AU - Chrischilles E; Delgado DJ; Stolshek BS; Lawless G; Fridman M; Carter WB
TI -
Impact of age and colony-stimulating factor use on hospital length of
stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma.
SO - Cancer Control 2002 May-Jun;9(3):203-11
AD - Department of Epidemiology, College of Public Health, University of
Iowa, Iowa City 52242, USA. chrischilles@uiowa.edu
BACKGROUND: In intermediate-grade non-Hodgkin's lymphoma (NHL) patients,
full-dose CHOP improves survival but increases myelosuppression, causing
febrile neutropenia hospitalization (FNH) in 28% of patients
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
